CN111514220A - Traditional Chinese medicine composition for treating coronary atherosclerotic heart disease and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating coronary atherosclerotic heart disease and preparation method thereof Download PDFInfo
- Publication number
- CN111514220A CN111514220A CN202010413354.4A CN202010413354A CN111514220A CN 111514220 A CN111514220 A CN 111514220A CN 202010413354 A CN202010413354 A CN 202010413354A CN 111514220 A CN111514220 A CN 111514220A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- heart disease
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 201000010238 heart disease Diseases 0.000 title claims abstract description 32
- 230000003143 atherosclerotic Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000000463 material Substances 0.000 claims abstract description 13
- 239000002552 dosage form Substances 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims description 29
- 210000003608 Feces Anatomy 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 241000301400 Trogopterus Species 0.000 claims description 20
- 241000037740 Coptis chinensis Species 0.000 claims description 17
- 235000004224 Typha angustifolia Nutrition 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 238000010298 pulverizing process Methods 0.000 claims description 17
- 241000233948 Typha Species 0.000 claims description 16
- 235000005391 Typha capensis Nutrition 0.000 claims description 16
- 235000019026 Typha domingensis Nutrition 0.000 claims description 16
- 235000005324 Typha latifolia Nutrition 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 13
- 239000012530 fluid Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000011230 binding agent Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 5
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims description 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 229940023488 Pill Drugs 0.000 claims description 4
- 230000002421 anti-septic Effects 0.000 claims description 4
- 230000001954 sterilising Effects 0.000 claims description 4
- 229960001681 Croscarmellose Sodium Drugs 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 229960001375 Lactose Drugs 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000004981 Coronary Disease Diseases 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 20
- 201000008739 coronary artery disease Diseases 0.000 abstract description 16
- 210000004369 Blood Anatomy 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 11
- 229940079593 drugs Drugs 0.000 abstract description 11
- 208000002193 Pain Diseases 0.000 abstract description 9
- 230000036407 pain Effects 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 230000001737 promoting Effects 0.000 abstract description 6
- 230000001105 regulatory Effects 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 5
- 239000000969 carrier Substances 0.000 abstract description 4
- 238000010926 purge Methods 0.000 abstract description 4
- 231100000486 side effect Toxicity 0.000 abstract description 3
- 230000004044 response Effects 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 206010008479 Chest pain Diseases 0.000 description 18
- 206010033557 Palpitations Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 210000004185 Liver Anatomy 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 210000004204 Blood Vessels Anatomy 0.000 description 4
- 210000002216 Heart Anatomy 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 206010002383 Angina pectoris Diseases 0.000 description 3
- 235000002991 Coptis groenlandica Nutrition 0.000 description 3
- 206010042434 Sudden death Diseases 0.000 description 3
- 208000001871 Tachycardia Diseases 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000000414 obstructive Effects 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 241000218202 Coptis Species 0.000 description 2
- 240000000628 Cyperus rotundus Species 0.000 description 2
- 208000002173 Dizziness Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010018987 Haemorrhage Diseases 0.000 description 2
- 208000010125 Myocardial Infarction Diseases 0.000 description 2
- 208000003067 Myocardial Ischemia Diseases 0.000 description 2
- 229940075582 Sorbic Acid Drugs 0.000 description 2
- 210000000952 Spleen Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- UEDUENGHJMELGK-VESORUSYSA-N Stevioside Natural products O=C(O[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 UEDUENGHJMELGK-VESORUSYSA-N 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 230000000740 bleeding Effects 0.000 description 2
- 231100000319 bleeding Toxicity 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- -1 excipients Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001965 increased Effects 0.000 description 2
- 230000000302 ischemic Effects 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N 1,2,3-propanetrioltrinitrate Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000891 Acute myocardial infarction Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 241000266855 Astragalus mongholicus Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000037803 Coptis deltoidea Species 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 210000004351 Coronary Vessels Anatomy 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000234653 Cyperus Species 0.000 description 1
- 235000016854 Cyperus rotundus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 210000000232 Gallbladder Anatomy 0.000 description 1
- LPLVUJXQOOQHMX-MYOOOWEVSA-N Glycyrrhizic acid Natural products O=C(O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](C(=O)O)O2)[C@@H](O[C@@H]2C(C)(C)[C@H]3[C@@](C)([C@H]4C(=O)C=C5[C@](C)([C@]4(C)CC3)CC[C@]3(C)[C@H]5C[C@](C(=O)O)(C)CC3)CC2)O1 LPLVUJXQOOQHMX-MYOOOWEVSA-N 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010028315 Muscle injury Diseases 0.000 description 1
- 210000004165 Myocardium Anatomy 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229940014995 Nitroglycerin Drugs 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 210000003516 Pericardium Anatomy 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940069328 Povidone Drugs 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000555746 Pteromys volans Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M Sodium stearate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042772 Syncope Diseases 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N Talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000301399 Trogopterus xanthipes Species 0.000 description 1
- 240000001398 Typha domingensis Species 0.000 description 1
- 241001518821 Typha orientalis Species 0.000 description 1
- 241000233945 Typhaceae Species 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000002107 myocardial Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005429 turbidity Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Abstract
The invention discloses a traditional Chinese medicine composition for treating coronary atherosclerotic heart disease and a preparation method thereof, belonging to the field of traditional Chinese medicine treatment of coronary heart disease. The invention firstly discloses a traditional Chinese medicine composition for treating coronary atherosclerotic heart disease, which comprises the following components: rhizoma Cyperi, Oletum Trogopterori, pollen Typhae and Coptidis rhizoma. On the basis of the traditional Chinese medicine composition, proper auxiliary materials or carriers are added, and the medicine with various dosage forms for treating coronary atherosclerotic heart disease can be prepared. The traditional Chinese medicine composition has reasonable compatibility, has the effects of promoting blood circulation to remove blood stasis, clearing heat and purging fire, and regulating qi to alleviate pain by combining the four raw material medicines, gives consideration to cold and heat, does not need to be classified, is suitable for treating various coronary heart diseases, can greatly improve and eliminate the symptoms of the coronary heart diseases, and has definite curative effect, quick response and no toxic or side effect.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition for treating coronary atherosclerotic heart disease and a preparation method of the traditional Chinese medicine composition, belonging to the field of traditional Chinese medicine treatment of coronary heart disease.
Background
Coronary atherosclerotic heart disease refers to heart disease caused by myocardial ischemia and anoxia due to obstruction of blood vessel cavity caused by coronary atherosclerosis, and is collectively called coronary heart disease (coronary heart disease, also called ischemic heart disease) together with functional change (spasm) of coronary artery. Coronary atherosclerotic heart disease presents three main symptoms: angina pectoris, myocardial infarction and latent coronary heart disease.
Atherosclerosis (AS) is a disease that mainly affects large and medium arteries, thickens, hardens and narrows the intima of blood vessels, and eventually leads to local insufficient or interrupted blood supply due to excessive narrowing of the blood vessel lumen, or causes myocardial infarction, cerebral apoplexy, ischemic necrosis of distal limbs and even sudden death due to local secondary thrombosis.
Coronary heart disease has become one of the most serious diseases threatening human health for half a century worldwide. For example, 1/3 of the total deaths in the united states are deaths due to coronary heart disease; 120 million patients suffer from acute myocardial infarction every year, and about 70 million patients die of coronary heart disease every year, wherein 35 million patients are sudden death of coronary heart disease. Finnish's incidence and mortality of coronary heart disease is the first in the world, and about 1/3 of the dead population is sudden death due to coronary heart disease. At present, the average prevalence rate of coronary heart disease in China is 7%, and the prevalence rate increases with age, and the incidence rate still tends to rise. Therefore, coronary heart disease has become a public nuisance worldwide.
The traditional Chinese medicine considers that the chest stuffiness and pains and the true heartache of the disease are caused; is mainly characterized by heart failure and heart syncope due to cold coagulation and phlegm turbidity, blood stasis and obstruction of heart vessels, heart muscle injury, deficiency of qi and yin, lung failure in dispersing and purifying or unsmooth circulation of qi and blood, blood stasis and water retention. Therefore, the development of the traditional Chinese medicine composition for treating the coronary atherosclerotic heart disease with definite curative effect has important significance and application prospect.
Disclosure of Invention
The first technical problem to be solved by the invention is to provide a traditional Chinese medicine composition for treating coronary atherosclerotic heart disease, which can greatly improve and eliminate the symptoms of coronary heart disease, and has high total effective rate and definite curative effect on the treatment of coronary atherosclerotic heart disease;
the invention also provides a preparation method of the traditional Chinese medicine composition.
In order to solve the technical problems, the technical scheme adopted by the invention is as follows:
the invention firstly discloses a traditional Chinese medicine composition for treating coronary atherosclerotic heart disease, which comprises the following components: rhizoma Cyperi, Oletum Trogopterori, pollen Typhae and Coptidis rhizoma. The weight parts of each component are as follows: 8-15 parts of rhizoma cyperi, 4-7 parts of trogopterus dung, 4-7 parts of cattail pollen and 1-3 parts of coptis chinensis.
Further preferably, the weight parts of the components are as follows: 9 parts of rhizoma cyperi, 6 parts of trogopterus dung, 6 parts of cattail pollen and 3 parts of coptis chinensis.
Rhizoma Cyperi is dried rhizome of Cyperus rotundus L. Pungent, slightly bitter, slightly sweet and mild in nature. It enters liver, spleen and triple energizer meridians. The functional indications are as follows: move qi and relieve depression, regulate menstruation and alleviate pain.
Trogopterus dung is dry feces of Trogopterus Xanthipes Milne-Edwards or Pteromys volans L. Sweet in nature and taste, warm. The functional indications are as follows: promoting blood circulation, removing blood stasis, and stopping bleeding by stir-frying with charcoal.
Pollen Typhae is dry pollen of Typhaceae plant Typha angustifolia L, Typha orientalis Presl or congeneric plant. Sweet in nature and taste and mild in nature. It enters liver and pericardium meridians. The functional indications are as follows: stop bleeding, resolve stasis, treat stranguria.
The rhizoma Coptidis is dried rhizome of Coptis chinensis Franch, Coptis deltoidea C.Y.Cheng et Hsiao or Coptis Teeta wall of Ranunculaceae. Bitter in property and cold in nature. It enters heart, spleen, stomach, liver, gallbladder and large intestine meridians. The functional indications are as follows: clear heat and dry dampness, purge fire and remove toxicity.
The traditional Chinese medicine composition for treating coronary atherosclerotic heart disease provided by the invention comprises the following components: the symptoms of the coronary heart disease are mainly the diseases of chest distress, palpitation, chest pain and dyspnea of a patient caused by the blockage of partial blood vessels of the heart and the obstruction of the circulation of cardiovascular qi and blood, so the formula firstly considers the medicines for regulating the flow of qi and activating the blood circulation. Monarch drug: cyperus rotundus, efficacy: soothing liver and relieving qi stagnation, regulating qi and relieving epigastric distention, it is indicated for liver qi stagnation and distending pain in chest and hypochondrium. Ministerial drugs: trogopterus dung, efficacy: promoting blood circulation, removing blood stasis, and relieving pain, and can be used for treating chest pain. Pollen Typhae and Coptidis rhizoma are used as adjuvant drugs, and pollen Typhae assists rhizoma Cyperi and Oletum Trogopterori to enhance the effects of promoting blood circulation and removing blood stasis; the coptis root has the effects of regulating cold and heat, assisting the cyperus tuber and the trogopterus dung to relieve pain, and the four medicines are combined to play the effects of promoting blood circulation to remove blood stasis, clearing heat and purging fire, and regulating qi to relieve pain.
The traditional Chinese medicine composition for treating coronary atherosclerotic heart disease has the clinical characteristics that: the traditional Chinese medicine composition has the advantages of both cold and heat, no need of typing, wide adaptation diseases and suitability for treating various types of coronary heart diseases.
The traditional Chinese medicine composition has the advantages of obvious curative effect, quick response and no obvious toxic or side effect when being used for treating the coronary atherosclerotic heart disease.
Clinical application tests show that the Chinese medicinal composition for treating the coronary atherosclerotic heart disease can greatly improve and eliminate the symptoms of the coronary heart disease after being taken for 1 course of treatment, has the significant efficiency of 92.8 percent, has the total effective rate of 100 percent, does not relapse after healing and has no side effect. Moreover, the obvious efficiency and the total effective rate of the traditional Chinese medicine composition prepared by matching rhizoma cyperi, trogopterus dung, cattail pollen and coptis chinensis are obviously higher than those of the traditional Chinese medicine composition prepared by matching rhizoma cyperi, the trogopterus dung, the cattail pollen and the coptis chinensis, or the rhizoma cyperi, the trogopterus dung, the pinellia ternate and the coptis chinensis, or the traditional Chinese medicine composition prepared by matching astragalus mongholicus, the trogopterus dung, the cattail pollen and the coptis chinensis. The results prove that the rhizoma cyperi, the trogopterus dung, the cattail pollen and the coptis have obvious synergistic interaction.
The invention also discloses a preparation method of the traditional Chinese medicine composition, which comprises the following steps: weighing the components according to the weight parts, crushing and uniformly mixing to obtain the composition.
The pulverization is not particularly limited in the present invention, and may be adjusted as necessary, and for reference, the pulverization is conducted to 150-mesh and 300-mesh.
The invention also discloses application of the traditional Chinese medicine composition in preparing a medicine for treating coronary atherosclerotic heart disease.
On the basis of the traditional Chinese medicine composition for treating coronary atherosclerotic heart disease, proper auxiliary materials or carriers are added to prepare the medicine for treating coronary atherosclerotic heart disease. Wherein the dosage form of the medicament includes but is not limited to: tablet, granule, capsule, pill, oral liquid or injection. Methods for preparing such pharmaceutical dosage forms are well known to those skilled in the art.
The carrier or the auxiliary material refers to a carrier or an auxiliary material which is conventional in the pharmaceutical field, such as: diluents, disintegrants, lubricants, excipients, binders, glidants, fillers, surfactants, and the like; in addition, other adjuvants such as flavoring agents and sweeteners may also be added to the composition. The diluent can be one or more components for increasing the weight and volume of the tablet, and common diluents comprise lactose, starch, pregelatinized starch, microcrystalline cellulose, sorbitol, mannitol, inorganic calcium salt and the like; the most common of them are lactose, starch, microcrystalline cellulose. The disintegrating agent can be one or a mixture of more of crosslinked polyvinylpyrrolidone (with the total weight ratio of 2-6%), crosslinked sodium carboxymethylcellulose (with the total weight ratio of 2-6%), alginic acid (with the total weight ratio of 2-5%), microcrystalline cellulose (with the total weight ratio of 5-15%); wherein the preferred ratio is crosslinked polyvinylpyrrolidone (2-7% by weight) and crosslinked sodium carboxymethylcellulose (2-6% by weight). The lubricant comprises one or a mixture of stearic acid, sodium stearate, magnesium stearate, calcium stearate, polyethylene glycol, talcum powder and hydrogenated vegetable oil; magnesium stearate is most preferred. The amount of the lubricant is in the range of 0.10 to 1% (by total weight), and is generally 0.25 to 0.75%, and preferably 0.5 to 0.7%. The binding agent can be one or more components which are beneficial to granulation; it may be starch slurry (10-30% by weight of the total binder), hydroxypropyl methylcellulose (2-5% by weight of the total binder), polyvinylpyrrolidone (2-20% by weight of the total binder), preferably an aqueous solution of polyvinylpyrrolidone in ethanol. The glidant can be one or a mixture of more of superfine silica gel powder, talcum powder and magnesium trisilicate. The surfactant may be one or more ingredients that improve wetting and increase drug dissolution, and is typically sodium lauryl sulfate (typically in the range of 0.2-6% by weight relative to the total weight).
For reference, the present invention provides a method for preparing the Chinese medicinal composition into tablets, comprising: pulverizing the above materials, adding starch, mixing, adding dextrin, adding 50% ethanol, making soft mass, granulating, drying, sieving, grading, adding magnesium stearate, mixing, and tabletting.
For reference, the present invention provides a method for preparing the Chinese medicinal composition into granules, comprising: pulverizing the above materials, mixing with microcrystalline cellulose, lactose, and croscarmellose sodium, adding binder to make soft mass, sieving, granulating, and drying. The binder may be a 3% povidone ethanol solution (50% concentration).
For reference, the present invention provides a method for preparing the Chinese medicinal composition into a capsule, comprising: pulverizing the above materials, decocting in water, mixing decoctions, filtering, and concentrating the filtrate to obtain fluid extract; mixing the fluid extract with appropriate amount of starch, drying, pulverizing, adding appropriate amount of ethanol, granulating, drying, grading, and making into capsule. Specifically, the raw materials are decocted for two times by adding water, the first time is decocted for 2 hours by adding 6 times of water by weight, and the second time is decocted for 1.5 hours by adding 4 times of water by weight; mixing the decoctions, filtering, and concentrating the filtrate to obtain fluid extract with relative density of 1.17-1.19(60 deg.C).
For reference, the invention also provides a method for preparing the traditional Chinese medicine composition into oral liquid, which comprises the following steps: pulverizing the above materials, decocting in water, mixing decoctions, filtering, and concentrating the filtrate to obtain fluid extract; adding appropriate amount of correctant, antiseptic and water into the fluid extract, mixing, packaging, and sterilizing. Specifically, the raw materials are decocted for two times by adding water, the first time is decocted for 2 hours by adding 6 times of water by weight, and the second time is decocted for 1.5 hours by adding 4 times of water by weight; mixing the decoctions, filtering, and concentrating the filtrate to obtain fluid extract with relative density of 1.17-1.19(60 deg.C). The sterilization is performed for 30 minutes at the temperature of 110 ℃ and under the pressure of 0.1 MPa. Common correctant includes Mel, simple syrup, glycyrrhizic acid and stevioside; the antiseptic is sorbic acid, benzoic acid, propionic acid, etc.
The raw materials used in the invention can be purchased in medical shops.
The use method and the dosage of the traditional Chinese medicine composition are as follows: the dosage of the invention depends on factors such as the specific dosage form, the age and the health condition of the patient, and the like. As a guide: the usage and dosage are as follows: the granule is orally taken 4-6 g each time, 3 times a day, and 1 month is a treatment course.
Compared with the prior art, the technical scheme of the invention has the following beneficial effects:
the invention applies the theory of traditional Chinese medicine and pharmacy and combines the modern pharmaceutical technology to prepare the pure traditional Chinese medicine preparation for treating coronary atherosclerotic heart disease. The traditional Chinese medicine composition provided by the invention is reasonable in compatibility, the four raw material medicines are combined to have the effects of promoting blood circulation to remove blood stasis, clearing heat and purging fire, and regulating qi to alleviate pain, and the traditional Chinese medicine composition has the advantages of taking cold and heat into consideration, being free from typing, being suitable for treating various coronary heart diseases, greatly improving and eliminating symptoms of the coronary heart diseases, being exact in curative effect, quick in effect taking and free from obvious toxic and side effects.
Detailed Description
The invention will be further described with reference to specific embodiments, and the advantages and features of the invention will become apparent as the description proceeds. It is to be understood that the described embodiments are exemplary only and are not limiting upon the scope of the invention. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be within the scope of the invention.
EXAMPLE 1 preparation of powders
Weighing the components (g) according to the following proportion: 8 parts of rhizoma cyperi, 4 parts of trogopterus dung, 4 parts of cattail pollen and 1 part of coptis chinensis; pulverizing to 150 mesh, and mixing.
EXAMPLE 2 preparation of powders
Weighing the components (g) according to the following proportion: 15 parts of rhizoma cyperi, 7 parts of trogopterus dung, 7 parts of cattail pollen and 3 parts of coptis chinensis; pulverizing to 300 mesh, and mixing.
EXAMPLE 3 preparation of powders
Weighing the components (g) according to the following proportion: 9 parts of rhizoma cyperi, 6 parts of trogopterus dung, 6 parts of cattail pollen and 3 parts of coptis chinensis; pulverizing to 200 mesh, and mixing.
EXAMPLE 4 preparation of powders
Weighing the components (g) according to the following proportion: 10 parts of rhizoma cyperi, 5 parts of trogopterus dung, 5 parts of cattail pollen and 2 parts of coptis chinensis; pulverizing to 250 mesh, and mixing.
EXAMPLE 5 preparation of tablets
Taking 15 g of the powder in example 1, adding 15 g of starch, uniformly mixing with 30 g of dextrin, and adding a proper amount of ethanol (50%) to prepare a soft material; granulating through a 16-mesh nylon sieve, drying at 60 ℃, sieving the dried granules again through a 16-mesh sieve for finishing granules, adding 5g of magnesium stearate, uniformly mixing and tabletting.
EXAMPLE 6 preparation of granules
Taking 3g of the powder in the embodiment 3, mixing with 5g of microcrystalline cellulose, 3g of lactose and 1 g of croscarmellose sodium, preparing a soft material by taking 3% povidone-ethanol solution (with the concentration of 50%) as a binding agent, sieving with a 40-mesh sieve for granulation, drying at 60 ℃, sieving with a 30-mesh sieve for granulation, and obtaining granules.
EXAMPLE 7 preparation of capsules
Weighing the following components (Kg) in proportion: 9 parts of rhizoma cyperi, 6 parts of trogopterus dung, 6 parts of cattail pollen and 3 parts of coptis chinensis; adding water for decocting twice, adding 6 times of water for the first time, decocting for 2 hours, adding 4 times of water for the second time, decocting for 1.5 hours; mixing the decoctions, filtering, and concentrating the filtrate to obtain fluid extract with relative density of 1.17-1.19(60 deg.C); mixing the above fluid extracts, adding appropriate amount of starch, mixing, drying, pulverizing, adding appropriate amount of ethanol, granulating, drying, grading, and making into capsule.
EXAMPLE 8 preparation of pellets
100g of the powder in the example 2 is mixed with 35g of microcrystalline cellulose, and water is added to be used as a bonding agent to prepare a vegetarian pill.
Coating the above pill with Opadry (gastric soluble type) of Shanghai Carlekang (COLORCON) coating technology, as coating material under the following conditions: selecting water as a dissolving agent, wherein the concentration of a coating solution is 18 percent, the weight of the coating is increased by 4 percent, and the air inlet temperature is 65 ℃; the temperature of a slice bed is 43 ℃; the atomization pressure is 2.0 bar; the coating pan rotation speed is 17rmp, and the feed flow rate is 3g/min, thus obtaining the pills.
EXAMPLE 9 preparation of oral liquid
Weighing the following components (Kg) in proportion: 9 parts of rhizoma cyperi, 6 parts of trogopterus dung, 6 parts of cattail pollen and 3 parts of coptis chinensis; adding water for decocting twice, adding 6 times of water for the first time, decocting for 2 hours, adding 4 times of water for the second time, decocting for 1.5 hours; mixing decoctions, filtering, collecting filtrate, concentrating the filtrate to fluid extract with relative density of 1.17-1.19(60 deg.C), adding appropriate amount of correctant stevioside, antiseptic sorbic acid and water, bottling, and wet-heat sterilizing at 110 deg.C under 0.1MPa for 30 min.
Test example 1 clinical efficacy observation of the Chinese medicinal composition for treating coronary atherosclerotic heart disease
56 patients with clinical diagnosis of coronary atherosclerotic heart disease, 31 men, 25 women, age 42-78 years, mean age 56 years; the main symptoms are: chest distress, cardiothoracic pain, palpitation, short breath, dyspnea, etc., and ischemic change in electrocardiographic examination;
dividing 56 patients into a test group and a control group randomly, wherein 28 patients in each group have no significant difference in disease course, disease condition and age; among them, the test group was treated with the capsule of example 7. The using method comprises the following steps: orally taking the medicine for three times a day, 6 g of the medicine for each time, taking 30 days of treatment as 1 course of treatment, and counting the curative effect after 1 course of treatment is finished; the control group was treated with nitroglycerin.
The evaluation standard of curative effect is as follows:
the effect is shown: normal electrocardiographic examination or obvious improvement of coronary blood supply, disappearance or basic disappearance of uncomfortable symptoms such as chest distress, chest pain, palpitation and the like, and obvious increase of energy and physical strength;
the method has the following advantages: the discomfort symptom is relieved, and the energy and the physical strength are enhanced;
and (4) invalidation: the discomfort symptoms are unchanged or even worsened.
The results of the comparison of clinical efficacy are shown in table 1.
TABLE 1 Observation of the clinical efficacy of the Chinese medicinal composition of the present invention in treating coronary atherosclerotic heart disease
The results show that the traditional Chinese medicine composition prepared from the rhizoma cyperi, the trogopterus dung, the cattail pollen and the coptis chinensis has a remarkable treatment effect on the coronary atherosclerotic heart disease; wherein, the effect is 26 persons, and the effect rate is 92.8%; the total effective rate is 100%; the results prove that the traditional Chinese medicine composition consisting of the rhizoma cyperi, the trogopterus dung, the cattail pollen and the coptis chinensis has a remarkable treatment effect on the coronary atherosclerotic heart disease. In the observation of treatment, patients taking the traditional Chinese medicine composition have no serious adverse reaction, and the blood, urine and feces of the patients are routine and the liver and kidney functions are not abnormal.
Typical case 1
After a certain woman is taken for 2 courses, the myocardial blood supply is obviously improved through the examination of electrocardiogram, the illness state is basically stable, the physical condition is improved before the patient is stopped for 1 year, and the patient does not relapse.
Typical case 2
Wangzhi, a man aged 58 years old, suffered from coronary atherosclerotic heart disease for 6 years, had body weakness, frequently appeared the phenomena of chest distress and pain, palpitation and restlessness, tachycardia and the like, and had no obvious improvement after long-term taking of various medicines; after 1 treatment course of the capsule of the embodiment 7 of the invention is taken for treatment, the physical condition is obviously improved, the symptoms of chest distress, chest pain, palpitation, tachycardia and the like are relieved, after 2 treatment courses of the capsule, the body is strong, the symptoms of chest distress, chest pain, palpitation, tachycardia and the like basically disappear, and the disease condition does not relapse after the capsule is taken for 1 year.
Typical case 3
Wenyiao, male, 46 years old, suffered from coronary atherosclerotic heart disease for more than 4 years, often accompanied by symptoms such as palpitation, short breath, chest distress, dizziness and tinnitus, and sometimes appeared angina pectoris or precordial pain, and the condition of coronary atherosclerotic heart disease confirmed by hospital is not obviously improved after taking various medicines; the treatment is introduced by people, after 1 course of treatment by taking the capsule of the embodiment 7 of the invention, discomfortable symptoms such as palpitation, short breath, chest distress, dizziness, tinnitus and the like gradually disappear, symptoms such as angina or precordial pain and the like are obviously relieved, and after 2 courses of treatment by continuing taking the capsule of the embodiment 7, the discomfortable symptoms basically disappear, and the disease does not relapse after follow-up after 1 year of medicine withdrawal.
Typical case 4
In a forest, a woman is aged 67 years old, the patient suffers from palpitation accompanied by symptoms such as facial edema, poor appetite, cough and asthma, and the like, particularly, at night, the sleep quality is seriously reduced, the physique is poor, the coronary atherosclerotic heart disease is diagnosed, the patient has no obvious effect after taking various medicines, and then the patient visits a doctor, after taking the capsule of the embodiment 7 of the invention for 1 treatment course, the chest distress short breath phenomenon is obviously relieved, the sleep quality is improved, the patient continues to take 2 treatment courses, feels smooth and uncomfortable to breathe, the palpitation and chest distress phenomena completely disappear, other clinical symptoms basically disappear, and the patient visits for half a year without relapse.
Claims (10)
1. A traditional Chinese medicine composition for treating coronary atherosclerotic heart disease is characterized by comprising the following components: rhizoma Cyperi, Oletum Trogopterori, pollen Typhae and Coptidis rhizoma.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following components in parts by weight: 8-15 parts of rhizoma cyperi, 4-7 parts of trogopterus dung, 4-7 parts of cattail pollen and 1-3 parts of coptis chinensis.
3. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following components in parts by weight: 9 parts of rhizoma cyperi, 6 parts of trogopterus dung, 6 parts of cattail pollen and 3 parts of coptis chinensis.
4. A method for preparing a Chinese medicinal composition as claimed in any one of claims 1 to 3, comprising the steps of: weighing the components according to the weight parts, crushing and uniformly mixing to obtain the composition.
5. Use of a Chinese medicinal composition according to any one of claims 1 to 3 in the manufacture of a medicament for the treatment of coronary atherosclerotic heart disease.
6. The use according to claim 5, wherein the medicament is in a dosage form comprising: tablet, granule, capsule, pill, oral liquid or injection.
7. Use according to claim 6, wherein the preparation of the tablet comprises: pulverizing the above materials, adding starch and dextrin, mixing, adding 50% ethanol, granulating, drying, sieving, adding magnesium stearate, mixing, and tabletting.
8. Use according to claim 6, wherein the preparation of the granules comprises: pulverizing the above materials, mixing with microcrystalline cellulose, lactose, and croscarmellose sodium, adding binder to make soft mass, sieving, granulating, and drying.
9. Use according to claim 6, wherein the preparation of the capsule comprises: pulverizing the above materials, decocting in water, mixing decoctions, filtering, and concentrating the filtrate to obtain fluid extract; mixing the fluid extract with appropriate amount of starch, drying, pulverizing, adding appropriate amount of ethanol, granulating, drying, grading, and making into capsule.
10. The use according to claim 6, wherein the preparation of the oral liquid comprises: pulverizing the above materials, decocting in water, mixing decoctions, filtering, and concentrating the filtrate to obtain fluid extract; adding appropriate amount of correctant, antiseptic and water into the fluid extract, mixing, packaging, and sterilizing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010413354.4A CN111514220A (en) | 2020-05-15 | 2020-05-15 | Traditional Chinese medicine composition for treating coronary atherosclerotic heart disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010413354.4A CN111514220A (en) | 2020-05-15 | 2020-05-15 | Traditional Chinese medicine composition for treating coronary atherosclerotic heart disease and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111514220A true CN111514220A (en) | 2020-08-11 |
Family
ID=71907604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010413354.4A Pending CN111514220A (en) | 2020-05-15 | 2020-05-15 | Traditional Chinese medicine composition for treating coronary atherosclerotic heart disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111514220A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102091163A (en) * | 2010-12-06 | 2011-06-15 | 济南金鼎信息技术有限公司 | Chinese medicine composition for treating diabetic heart disease |
| CN104524535A (en) * | 2015-01-15 | 2015-04-22 | 范丰双 | Traditional Chinese medicine composition for treating chronic pulmonary heart disease and preparation method of traditional Chinese medicine composition |
| CN104906399A (en) * | 2015-06-16 | 2015-09-16 | 郭前进 | Traditional Chinese medicine pills for treating heart disease and preparation method of traditional Chinese medicine pills |
-
2020
- 2020-05-15 CN CN202010413354.4A patent/CN111514220A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102091163A (en) * | 2010-12-06 | 2011-06-15 | 济南金鼎信息技术有限公司 | Chinese medicine composition for treating diabetic heart disease |
| CN104524535A (en) * | 2015-01-15 | 2015-04-22 | 范丰双 | Traditional Chinese medicine composition for treating chronic pulmonary heart disease and preparation method of traditional Chinese medicine composition |
| CN104906399A (en) * | 2015-06-16 | 2015-09-16 | 郭前进 | Traditional Chinese medicine pills for treating heart disease and preparation method of traditional Chinese medicine pills |
Non-Patent Citations (2)
| Title |
|---|
| 徐小明等: "香附在冠心病治疗中的应用", 《山西中医》 * |
| 杨传彪等: "冠心病心绞痛常用方剂及其临床运用（一）", 《安徽中医临床杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100544763C (en) | A kind of Chinese medicine for the treatment of coronary heart disease | |
| CN104147536A (en) | Medicine composition for treating haemorrhoids and preparation method thereof | |
| CN100391494C (en) | Compound chinese preparation for treating pain symptom and its preparing process | |
| CN108159213A (en) | It is a kind of to be used to treat Chinese medicine composition of coronary heart disease and preparation method thereof | |
| CN111514220A (en) | Traditional Chinese medicine composition for treating coronary atherosclerotic heart disease and preparation method thereof | |
| CN105770691A (en) | Medicinal preparation for treating cervical cancer and application thereof | |
| CN101590173B (en) | Application of traditional Chinese medicine composition in preparing medicine for treating hypertensive intracerebral hemorrhage | |
| CN104666702A (en) | Traditional Chinese medicine composition for treating acute and chronic enteritis, colitis and bowel dysfunction | |
| CN104984097A (en) | Chinese herba preparation for treating primary hypertension and application thereof | |
| CN104800675A (en) | Medicament for treating active ulcerative colitis | |
| CN101732469B (en) | Application of Chinese medicinal composition in preparation of medicament for treating aphonia | |
| CN111467408B (en) | Traditional Chinese medicine composition for clearing heat and removing toxicity, nourishing yin and reducing fire and preparation method thereof | |
| CN103768129A (en) | Drug composition for preventing or treating hypertension | |
| CN104435657B (en) | A kind of medicine for preventing and treating prostate cancer endocrine therapy side effect and preparation method thereof | |
| CN106880673A (en) | It is a kind of to treat Chinese medicine composition of coronary heart disease and preparation method thereof | |
| CN112494598B (en) | Effective part composition for treating pharyngitis and application thereof | |
| CN101744905B (en) | Applications of Chinese medicinal composition in preparation of medicament for treating pulmonary heart disease | |
| CN107233410B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| CN105250409A (en) | Traditional Chinese medicine composition for treating hypertension | |
| CN105327145A (en) | Composition for treating hypertensive cerebral hemorrhage and preparation method thereof | |
| CN115624605A (en) | Traditional Chinese medicine composition for treating ovarian endometriosis | |
| CN103191350A (en) | Traditional Chinese medicine composition for treating gallstones and preparation method thereof | |
| CN110538251A (en) | Traditional Chinese medicine composition for treating prostate diseases and preparation method and application thereof | |
| CN103893346B (en) | One treats ARR Chinese medicine of motive asthenia type and preparation method thereof | |
| CN114053386A (en) | Traditional Chinese medicine composition and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200811 |